For research use only. Not for therapeutic Use.
Lenacapavir（Cat No.:I017901）is a first-in-class capsid inhibitor developed for the treatment of HIV-1 infection. It targets the HIV-1 capsid, a crucial protein involved in multiple stages of the viral lifecycle, including viral assembly, disassembly, and replication. By disrupting these processes, lenacapavir prevents the virus from multiplying and spreading. Its long-acting formulation, allowing for infrequent dosing, offers a convenient treatment option for patients, particularly those with multidrug-resistant HIV. Lenacapavir is a promising addition to HIV therapy, improving treatment adherence and enhancing viral suppression in difficult-to-treat cases.
| Catalog Number | I017901 |
| CAS Number | 2189684-44-2 |
| Molecular Formula | C₃₉H₃₂ClF₁₀N₇O₅S₂ |
| Purity | 99% |
| Target | HIV p24 |
| Target Protein | P03366 |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | MT-4 cells:100 pM (EC50) |
| IUPAC Name | N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)pyridin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide |
| InChI | InChI=1S/C39H32ClF10N7O5S2/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H,52,58)(H,54,55)/t24-,25+,27-/m0/s1 |
| InChIKey | BRYXUCLEHAUSDY-WEWMWRJBSA-N |
| SMILES | CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)[C@H](CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C([C@H]7C[C@H]7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C |
| Reference | [1]. Singh K, et al. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019 Jun 20;10:1227.<br>[2]. John O Link, et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Jul 1. |
